The procurement documents are available for unrestricted and full direct access, free of charge at:
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:
Ministry or any other national or federal authority, including their regional or local subdivisions
Lot No: 1
II.2.1) Title
Lot 1 - eftrenonacog alfa (rFIX EHL)
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
Lot 2 - albutrepenonacog alfa (rFIX EHL)
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
Lot 3 - nonacog beta pegol (rFIX EHL)
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 4
II.2.1) Title
Lot 4 - rFIX - Standard Half Life
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 5
II.2.1) Title
Lot 5 - Recombinant Factor VII
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 6
II.2.1) Title
Lot 6 - Porcine Factor VIII - susoctocog alfa
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 7
II.2.1) Title
Lot 7 - Factor VIII Inhibitor Bypassing Fraction
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 8
II.2.1) Title
Lot 8 - Factor IX - High Purity Factor IX
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 9
II.2.1) Title
Lot 9 - Factor X
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 10
II.2.1) Title
Lot 10 - Factor XIII - Plasma Derived
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 11
II.2.1) Title
Lot 11 - Factor XIII - Recombinant
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 12
II.2.1) Title
Lot 12 - Factor VIII/ von willebrands factor
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 13
II.2.1) Title
Lot 13 - Von willebrands factor - Plasma Derived
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 14
II.2.1) Title
Lot 14 - Von willebrands factor - Recombinant
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 15
II.2.1) Title
Lot 15 - Fibrinogen Concentrate
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 16
II.2.1) Title
Lot 16 - Prothrombin Complex dried
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 17
II.2.1) Title
Lot 17 - Protein C Concentrate
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 18
II.2.1) Title
Lot 18 - Fresh Frozen Plasma
II.2.2) Additional CPV code(s)
33141530
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above
II.2.4) Description of the procurement
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
1.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/07/2022
End:
30/06/2024
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
Yes
Description of options:
Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
RESPONDING TO THIS NOTICE:<br/>Any supplier may be disqualified who does not respond to the following in the requisite manner:<br/>1) Submission of expression of interest and procurement specific information<br/>This procurement exercise will be conducted on the eTendering portal at<br/>https://healthfamily.force.com/s/Welcome<br/>Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific<br/>information (if requested) through the eTendering portal as follows:<br/>1.1) If not already registered, Candidatesshould register on the eTendering portal at<br/>https://health-family.force.com/s/Welcome and<br/>click the link to register:<br/>- agree to the user agreement<br/>- populate company details<br/>1.2) Once registered, candidates must register interest as follows:<br/>- log to the portal<br/>- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select <br/>review opportunity details and click "Register Interest"<br/>- as you select the opportunity, you can review documents, send clarification messages,submit the response or decline to respond (if<br/>you decide not to participate in the opportunity)<br/>1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis help desk at supporthealth@<br/>atamis.co.uk or by calling 0800 9956035 for technical assistance when<br/>completing responses.<br/>2) General supplier information.<br/>To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:<br/>2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the<br/>following web page<br/>https://supplierregistration.cabinetoffice.gov.uk and select "Register" at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S®Number, click on the link at the right of the page to obtain a number from D&B.<br/>Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.<br/>2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.<br/>D&B data will be supplied automatically by D&B.<br/>2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the message function on the website.<br/>OTHER CONTRACTING AUTHORITIES<br/>The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together<br/>as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or<br/>goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare<br/>or health related services.